WORCESTER, Mass., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today commented on the consensus algorithm for Type 2 diabetes treatment issued by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published online on October 22, 2008 (Diabetes Care, volume 31, number 12, December 2008).
